ALSO NOTED: Nycomed, Ceremed sign deal; Optimer raises $35.9M in private placement; GSK braces for cuts; and much more...

> Nycomed and Ceremed have signed a licensing and distribution pact for Ostene, a product designed to stop bone bleeding in surgery. Release

> Optimer Pharmaceuticals has raised $35.9 million from the private placement of 4.6 million newly issued shares of its common stock, at a price of $7.80 per share. Release

> The axe is about to drop at GlaxoSmithKline. The drug maker reported a 5.8 percent drop in profits to $2.77 billion--partly due to generic competition, but largely from a 48 percent slide in Avandia sales. Report

> Roche's siege on Amgen anemia-drugs territory is ending with a whimper. A jury ruled that the Swiss drug maker's Mircera product infringes three Amgen patents. Short of "evaluating its legal options" in hopes of a valid appeal, there's little Roche can do to fight back now. Report

> The cold-drug controversy is widening. Now, the FDA has asked an advisory panel to investigate phenylephrine, a new decongestant ingredient in many over-the-counter remedies. Report

> Gene mutations in the A beta protein are assisting these proteins in clumping together, which in turn is promoting Alzheimer's, according to a scientific team at UCLA. Report

> A molecular mechanism at work during periods of stress may shed light on developing new therapies for post-traumatic stress disorder and other conditions. Report

> Pfizer has closed its La Jolla campus due to the fire emergency in California. Release

And Finally... The race is on for muscle-enhancing therapies. Report

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Pfizer's eczema hopeful has been building its case to challenge Sanofi and Regeneron's Dupixent, but safety issues could stand in its way.

Cedrik Britten, M.D., becomes the biotech’s new chief medical officer to help run its adoptive cell therapy and TCR bispecifics platform.